Another emerging candidate molecular target for CLL treatment is the elongation factor 1 A (eEF1A) involved in the enzymatic delivery of aminoacyl-tRNAs to the ribosome (“canonical function”) and in cell cycle and apoptosis regulation (“non-canonical functions”) [83,84]. This evidence concerns the gene EEF1A1 and B-cell chronic lymphocytic leukemia.